Second, by analysis of individual patient data we showed
that this benefi t was due mainly to a delayed reduction
of about 30–40% in deaths after 5 years of treatment.
Third, by long-term follow-up of three large trials we
showed that the reduction in deaths due to solid cancers
was maintained for 20 years, only becoming apparent
for some cancers after completion of the trials. Fourth